DEXDOR

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, Finland, France, Ireland, Lithuania, Netherlands, Poland, Spain, UK.

Active ingredients

The drug DEXDOR contains one active pharmaceutical ingredient (API):

1	Dexmedetomidine UNII 1018WH7F9I - DEXMEDETOMIDINE HYDROCHLORIDE
	Dexmedetomidine is a selective alpha-2 receptor agonist with a broad range of pharmacological properties. It has a sympatholytic effect through decrease of the release of noradrenaline in sympathetic nerve endings. The sedative effects are mediated through decreased firing of locus coeruleus, the predominant noradrenergic nucleus, situated in the brainstem.
	Read more about Dexmedetomidine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DEXDOR Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05CM18	Dexmedetomidine	N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives → N05CM Other hypnotics and sedatives
Discover more medicines within N05CM18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1540336, 1540347, 1540358, 1540369
ES	Centro de información online de medicamentos de la AEMPS	11718002, 11718006
FI	Lääkealan turvallisuus- ja kehittämiskeskus	390699, 470397
FR	Base de données publique des médicaments	64634939
GB	Medicines & Healthcare Products Regulatory Agency	195381, 195385, 195388
LT	Valstybinė vaistų kontrolės tarnyba	1062981, 1062982, 1062984, 1062986, 1072972
NL	Z-Index G-Standaard	15742199, 15742210, 15742229
NL	Z-Index G-Standaard, PRK	99791, 99805, 99813
PL	Rejestru Produktów Leczniczych	100254789